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The discovery of novel bioactive molecules advances our systems-level understanding of biological
processes and is crucial for innovation in drug development. For this purpose, the emerging ﬁeld of
chemical genomics is currently focused on accumulating large assay data sets describing
compound–protein interactions (CPIs). Although new target proteins for known drugs have
recently been identiﬁed through mining of CPI databases, using these resources to identify novel
ligandsremainsunexplored.Herein,wedemonstratethatmachinelearningofmultipleCPIscannot
onlyassessdrugpolypharmacologybutcanalsoefﬁcientlyidentifynovelbioactivescaffold-hopping
compounds. Through a machine-learning technique that uses multiple CPIs, we have successfully
identiﬁed novel lead compounds for two pharmaceutically important protein families, G-protein-
coupled receptors and protein kinases. These novel compounds were not identiﬁed by existing
computational ligand-screening methods in comparative studies. The results of this study indicate
that data derived from chemical genomics can be highly useful for exploring chemical space, and
this systems biology perspective could accelerate drug discovery processes.
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Introduction
Experimental perturbations of biological systems, such as
genetic mutation and chemical exposure, have been used as
powerful approaches to deepen our systems-level under-
standing of biological processes and to discover unprece-
dentedbiological phenomena (Leha ´ret al, 2008). In particular,
perturbations by chemical probes provide broader applica-
tions not only for analysis of complex systems but also for
intentional manipulations of these systems, e.g., a medicine is
a small molecule designed for the purpose of clinical therapy
that can actively manipulate biological systems from dis-
ordered to well-ordered states. Unfortunately, the number of
well-characterized chemical probes is highly limited, which
has bottlenecked their wide range of application.
Thesetofallpossiblesmallorganicmolecules,referredtoas
chemical space, has been estimated to consist of more than
10
60 compounds (Dobson, 2004). Chemical space is as vast as
the diversity of biological systems, and the vastness of the two
domains creates difﬁculty in comprehensive understanding
of the interface between chemical space and biological
systems (Lipinski and Hopkins, 2004; Renner et al, 2009).
Recently, chemical genomics has emerged as a promising area
of research applicable to exploration of novel bioactive
molecules, and researchers are currently striving toward the
identiﬁcation of all possible ligands for all target protein
families (Wang et al, 2009). Large-scale data sets of
compound–protein interactions (CPIs) are being collected,
and chemical genomics studies have shown that patterns of
protein–ligand interactions are too diverse to be understood as
simple one-to-one events. For example, multiple structurally
different compounds have been shown to bind the same
protein or express similar biological activities (Eckert and
Bajorath,2007; Younget al, 2008). In othercases, onedrug has
been shown to affect multiple targets from different protein
families (MacDonald et al, 2006; Paolini et al, 2006). This
phenomenon, termed polypharmacology, is thought to be one
critical cause of adverse drug effects (Hopkins, 2008). There-
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among chemical and biological components beyond a one-
compound/one-target simpliﬁcation could open up new
opportunities in drug development, but the need to develop
appropriate data mining methods for characterizing and
visualizing the full complexity of interactions between
chemical space and biological systems is urgent (Oprea et al,
2007).Recently,miningofmultipleCPIdatasetshasbeenused
to identify new protein targets for known drugs and thereby
predict unreported polypharmacology (Keiser et al, 2009).
However, this approach only identiﬁes additional targets for
known drugs. No existing screening approach has so far
succeeded in identifying novel bioactive compounds using
multiple interactions among compounds and target proteins,
and the potential application of analysis of multiple CPIs to
identify novel bioactive molecules remains unknown.
High-throughput screening (HTS) and computational
screening have greatly aided in the identiﬁcation of early lead
compounds for drug discovery. However, the large numbers of
assays required for HTS to identify drugs that target multiple
proteins render this process very costly and time-consuming.
Therefore,interestinusinginsilico strategiesforscreeninghas
been increasing. The most common computational ap-
proaches, ligand-based virtual screening (LBVS) and struc-
ture-based virtual screening (SBVS; Oprea and Matter, 2004;
MueggeandOloff,2006;McInnes,2007;Figure1A),havebeen
used for practical drug development. Unfortunately, these
methods have important limitations. LBVS aims to identify
molecules that areverysimilar to known active molecules and
generally has difﬁculty identifying compounds with novel
structural scaffolds that differ from reference molecules.
Attempts to scaffold-hop using LBVS are prone to identiﬁca-
tion of increased numbers of false positives (Eckert and
Bajorath, 2007). Therefore, the primary objective of virtual
screening, reduction of the number of candidate compounds
to be assayed, remains unachievable using this method.
The other popular strategy, SBVS, is constrained by the
number of three-dimensional crystallographic structures
available and, more importantly, by the difﬁculty of accurately
simulating molecular docking processes for targets, including
membrane-spanning G-protein-coupled receptors (GPCRs).
To circumvent these limitations, we have shown that a new
computational screening strategy, chemical genomics-
based virtual screening (CGBVS), has the potential to identify
novel, scaffold-hopping compounds and assess their poly-
pharmacology by using a machine-learning method to
recognize conserved molecular patterns in comprehensive
CPI data sets.
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Figure 1 Overview and performance of CGBVS. (A) Comparison of the strategies used for CGBVS, LBVS, and SBVS. CGBVS used multiple CPI data, represented
theCPIinvectorform,andusedSVMforCPIpatternlearning.(B)ROCcurvesobtainedbyﬁvefoldcross-validationusingcompound–GPCRinteractionsfortheCGBVS
(red) and LBVS methods. The best accuracy rate for each method is also shown. NN–PCA (light blue), nearest neighbor (NN) method with the Pearson correlation
coefﬁcientintheconstructedspaceusingprincipalcomponentanalysis(PCA);NN–TC(navy),NNmethodwiththeTanimotocoefﬁcient(TC);andNN–PCC (purple),NN
method with the Pearson correlation coefﬁcient (PCC) in the original space. (C) Enrichment curves obtained by the CGBVS and SBVS methods. Glide was used both
without constraints and with constrained hydrogen bonding between the compounds and Asp113, a residue known to be crucial for ligand binding to ADRB2 (Strader
et al, 1987). Information regarding interactions between ADRB2 and its ligands was not used in test set for machine learning for CGBVS.
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Theoretical framework for CGBVS
The CGBVS strategy is made up of ﬁve steps: CPI data
collection, descriptorcalculation, representation ofinteraction
vectors,predictivemodelconstructionusingtrainingdatasets,
and predictions from test data (Figure 1A and Supplementary
FigureS1). Importantly, step1, the constructionof adata setof
chemical structures and protein sequences for known CPIs,
does not require the three-dimensional protein structures
needed for SBVS. We chose GPCRs, important pharmaceutical
targets (Hopkins and Groom, 2002), as our ﬁrst target proteins
for virtual ligand screening. In total, 5207 CPIs (including
317 GPCRs and 866 ligands) retrieved from the GLIDA
database (Okuno et al, 2006) were used as experimental data
(Supplementary Table S1). In step 2, compound structuresand
protein sequences were converted into numerical descriptors
using 929-dimensional and 400-dimensional feature vectors,
respectively. A wide variety of chemical descriptors was used
to describe the substructures, as well as the physicochemical
and molecular properties of the small molecules. Descriptors
for protein sequences were created using a string kernel (see
Materials and methods section and Supplementary informa-
tion for details). These descriptors were used to construct
chemical or biological spaces, in which decreasing distance
between vectors corresponded to increasing similarity of
compound structures or protein sequences. In step 3, we
represented multiple CPI patterns by concatenating these
chemical and protein descriptors (in 929þ400 dimensions).
Using these interaction vectors, we could quantify the
similarity of molecular interactions for compound–protein
pairs, despite the fact that the ligand and protein similarity
maps differed substantially (Keiser et al, 2007). In step 4,
concatenated vectors for CPI pairs (positivesamples) and non-
interacting pairs (negative samples) were input into a support
vector machine (SVM; Vapnik, 1995), an established machine-
learning technique widely applied to pattern-recognition
problems (Scho ¨lkopfet al, 2004;Shawe-Taylorand Cristianini,
2004).Usingtrainingsets,anSVMclassiﬁerwasgeneratedasa
hyperplane dividing positive and negative samples into two
distinct classes representing interaction and non-interaction.
By mapping the samples into high-dimensional feature space
using a nonlinear kernel function, samples that were linearly
inseparable in the original input space could be linearly
separated in the feature space. As a nonlinear SVM can extract
patterns from data sets with nonlinear characteristics, non-
intuitive interaction rules can be obtained from multiple CPI
patterns, creating the potential to identify novel CPIs. In the
ﬁnal step, the SVM classiﬁer constructed using training sets
was applied to test data. Along with providing simple yes/no
outputs, the calculated prediction scores also ranked all test
compound–GPCR pairs in the order of binding probability.
Computational evaluation of CGBVS
To evaluate the predictive value of CGBVS, we compared its
performancewiththatofLBVSmethodologiesusingrespective
data sets of 5207 interacting and non-interacting pairs. The
performance of each method was tested by repeating ﬁvefold
cross-validations 20 times. CGBVS performed with a consider-
ably higheraccuracy (91.9±0.3%) than LBVS (84.4±0.3%, at
best). We also recorded the number of true-positive interac-
tions as a function of false positives and plotted receiver
operating characteristic (ROC) curves (Hanley and McNeil,
1982), as shown in Figure 1B and Supplementary Table S2.
ROC analysis revealed that CGBVS performed better than all
LBVS methods in terms of the score ranking of CPI pairs.
Recently, the crystal structure of the b2-adrenergic receptor
(ADRB2) has been determined (Cherezov et al, 2007;
Rasmussen et al, 2007). Therefore, we were able to compare
CGBVS and SBVS in a retrospective virtual screening based on
the human ADRB2 using a representative docking program,
Glide (Friesner et al, 2004). For CGBVS, we constructed a
predictive model based on 5167 CPI pairs,excluding 40 known
ADRB2-relatedCPIstoavoidanybiasinfavorofCGBVSduring
the machine-learning step. Using both methods, we predicted
scores for the same 866 known GPCR ligands, including the 40
known ADRB2 ligands as positive controls. We asked whether
thescoresforthese40knownpositivecompoundswerehigher
than scores for other compounds. Figure 1C and Supplemen-
tary Table S3 show that CGBVS provided higher enrichment
factors(EFs) and hit rates than did SBVS.Theseresultssuggest
that CGBVS is more successful than conventional approaches
for prediction of CPIs.
Polypharmacological interactions for ADRB2
We also evaluated the ability of the CGBVS method to predict
the polypharmacology of ADRB2 by attempting to identify
novel ADRB2 ligands from the above ligand data set. As an
established, well-studied pharmaceutical target (Waldeck,
2002), we expected that novel ADRB2 ligands would be
difﬁcult to ﬁnd, and that searching for novel scaffolds for such
a well-known target would be a stringent assessment of the
predictive ability of CGBVS. After training an SVM classiﬁer
using all 5207 CPIs, we ranked the prediction scores for the
interactions of 826 reported GPCR ligands (excluding the 40
knownADRB2ligands) withADRB2, andthen analyzedthe50
highest-ranked compounds in greater detail. To complement
the less-than-comprehensive binding data available in the
original GLIDA database, a literature search was performed
using SciFinder (Wagner, 2006) and PubMed (http://
www.ncbi.nlm.nih.gov/pubmed/). This search identiﬁed 15
of the top 50 compounds as known ADRB2 ligands.
Importantly, these compounds were identiﬁed as ligands of
other GPCRs, not of ADRB2, in training sets used in the
machine-learning step. ADRB2 ligands already reported in the
literaturewereexcludedfromanalysis,buttheremainderwere
tested in in vitro binding assays. From the remaining 35
ligands, 21 were commercially available. Of these 21, 11 were
notpreviouslyreported,butwerediscoveredtobindtoADRB2
(Figure 2A and Supplementary Table S5). These compounds
included ligands for the acetylcholine, serotonin, dopamine,
and neuropeptide Y receptors (Figure 2E), indicating the
presence of potential polypharmacological interactions
with ADRB2.
To substantiate the novelty of the ligands identiﬁed by
CGBVS, we compared the predictive scores estimated by the
three virtual screening approaches (CGBVS, LBVS, and SBVS).
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50 compounds predicted by CGBVS that had ligand activity,
but that had not been used in the training data set, to evaluate
the other methods. As shown in Figure 2B and D, the known
ADRB2 ligands (orange dots) clustered with the highest scores
onthe LBVSaxis,whereasmost ofthe otheractivecompounds
identiﬁed (green dots) fell outside the top 50 scores. Active
compounds (red, orange, and green) were widely scattered
alongtheSBVSaxis(Figure2CandD),andonlysixwerefound
in the top 50 SBVS scores. This was consistent with the known
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Figure 2 Prediction of ADRB2 ligands. (A) Binding curves for 21 of the top 50 compounds ranked by CGBVS available commercially. Pink, BIBP3226 (1); purple,
granisetron (2); dark yellow, tropisetron (3); light blue, BW723C86 (4) (Supplementary Table S5); green, 11 active compounds screened (Kio100mM); and blue,
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correlation coefﬁcient between each compound and its nearest ligands in principal component space. Red, ADRB2 ligands; orange, ligands reported in the literature;
green, screened active compounds; and blue, inactive compounds. The numbers 1–4 are corresponding to BIBP3226 (1), granisetron (2), tropisetron (3), BW723C86
(4), respectively. Dotted lines show the score of the ﬁftieth-ranked compound using each method. (E) Polypharmacological relationships of newly identiﬁed ADRB2
ligands. Newly identiﬁed (green) and known (orange) ADRB2 ligands were mapped on a human GPCR phylogenetic tree (Fredriksson et al, 2003). The size of the
circles indicates the number of compounds reported to bind to each GPCR on the tree. Target GPCRs of the four compounds 1–4 are shown in the circles. 5HT2A,
5-hydroxytryptamine receptor 2A; 5HT2B, 5-hydroxytryptamine receptor 2B; 5HT4R, 5-hydroxytryptamine receptor 4; 5HT5A, 5-hydroxytryptamine receptor 5A;
ACM1, acetylcholine receptor M1; ADA1A, alpha 1-adrenergic receptor type A; ADA1B, alpha 1-adrenergic receptor type B; ADA1D, alpha 1-adrenergic receptor
typeD;ADA2A,alpha2-adrenergicreceptortypeA;ADA2B,alpha2-adrenergicreceptortypeB;ADA2C,alpha2-adrenergicreceptortypeC;ADRB1,beta1-adrenergic
receptor; ADRB3, beta 3-adrenergic receptor; DRD1, dopamine receptor D1; DRD2, dopamine receptor D2; DRD3, dopamine receptor D3; DRD4, dopamine
receptor D4.
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of SBVS in accurate scoring. Figure 2B–D shows that use
of CGBVS resulted in the identiﬁcation of the majority of the
novel active compounds (green dots), few of which were
identiﬁed by LBVS or SBVS. Four of these compounds (1–4 in
Table I and Supplementary Table S4) contained novelscaffolds
compared with known ADRB2 agonists (catecholamine or
isoprenaline derivatives) or ADRB2 antagonists (arylalkyl-
amine derivatives). Notably, these compounds included a
neuropeptide Y-type 1 receptor (NPY1R) antagonist (1). This
observation suggests that only CGBVS could identify this
unexpected cross-reaction for a ligand developed as a target to
a peptidergic receptor that has low protein homology to
ADRB2 (Figure 2E).
Polypharmacology map of the GPCR family
To identify possible polypharmacological relationships among
GPCRs, we constructed polypharmacology maps, ﬁrst based
on multiple interactions between GPCRs and their ligands
predicted by CGBVS, and second based on previously reported
interactions (Figure 3). CGBVS predicted many unexpected
multiple interactions between GPCRs and ligands, including,
interestingly, interactions shared by members of distantly
related subfamilies. (See Supplementary Figure S2 for a
correlation map of ligands and orphan GPCRs with no known
ligands.) To better understand the propensity for ligand
promiscuity, we extracted chemical substructures character-
istic of the putatively promiscuous ligands (Supplementary
Figure S3), as described in the Supplementary information.
This analysis has shown that tertiary amine and sulfur-
containing heterocycles are recurring substructures in the
promiscuous ligands when compared with selective ligands
(Supplementary Table S6). For example, these substructures
are typically seen in antidepressants used to treat depression
and anxiety disorders, which interact promiscuously with a
rangeof dopamine and serotonin receptors(Roth et al, 2004a).
This observation suggests that the ligands containing such
substructures can be non-selective.
Unlike CGBVS, SBVS cannot predict CPIs for multiple
GPCRs, because only limited three-dimensional structural
information is available. LBVS is applicable only to targets
with known reference ligands and is therefore unsuitable for
identifying polypharmacological interactions, particularly
Table I Compound IDs and names (see Supplementary Table S4 for the chemical structures)
Compound GLIDA ID Bionet ID Compound name
1 L000117 BIBP3226
2 L003700 Granisetron
3 L002023 Tropisetron
4 L000152 BW723C86
5 MS-2742 2,5-Dimethyl-1-(2,2,4-trimethyl-2,3-dihydro-1-benzofuran-7-yl)-1H-pyrrole
6 L001048 Codeine
7 L000315 Iodocyanopindolol
8 L001311 12L-933 1-(Tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]-2-propanol
9 MS-2807 (2-Aminophenyl)(4-methylphenyl)amine
10 L013420 Phentolamine
11 L001089 Desipramine
12 7W-0360 Ethyl 1-(4-chlorophenyl)-4-[(4-methoxybenzyl)amino]-3-methyl-1H-pyrazolo[3,4-b]pyridine-
5-carboxylate
13 L001167 Cartazolate
14 3-(6-Aminopyridin-3-yl)-2-(diphenylacetamido)-N-(4-methoxybenzyl)-N-methylpropionamide
15 3H-950 Diethyl 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-hydroxy-3,5-pyridinedicarboxylate
16 L000717 Nicergoline
17 3-Ethyl-5-[4-(4-ﬂuorophenyl)-4-(6-ﬂuoropyridin-3-yl)- 5-methyl-4,5-dihydro-1H-imidazol-2-yl]-1-
methylpyridin-2(1H)-one
18 11N-058 6,7-Dimethoxy-N-phenyl-4-quinazolinamine
19 1-(5-Tert-butyl-isoxazol-3-yl)-3-[4-(2-chloro-6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-urea
20 5-[6-Methoxy-7-(pyridin-4-ylmethoxy)-quinazolin-4-ylamino]-2-methyl-phenol
21 12N-063 N-{2-[(4-chlorophenyl)sulfanyl]ethyl}-6,7-dimethoxy-4-quinazolinamine
22 1-(6,7-Dimethoxy-2-pyridin-4-yl-quinazolin-4-ylamino)-indan-2-ol
23 MS-2894 [2-(4-Fluorophenyl)-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]benzothiazol-3-yl]methanol
24 2-Methyl-6-[6-(6-methyl-pyridin-2-yl)-imidazo[2,1-b]thiazol-5-yl]-3a,7a-dihydro-benzooxazole
25 1-{4-[4-Amino-5-(2,6-diﬂuoro-benzoyl)-thiazol-2-ylamino]-piperidin-1-yl}-8-methyl-
non-6-en-1-one
26 7N-773 [4-Amino-2-(tert-butylamino)-1,3-thiazol-5-yl](4-chlorophenyl)methanone
27 (4-Amino-2-phenylamino-thiazol-5-yl)-(4-chloro-3-methyl-phenyl)-methanone
28 9X-0942 2-[2,5-Dimethyl-4-(morpholinomethyl)phenoxy]acetamide
29 2W-0814 N-(tert-butyl)-N0-(4-methoxybenzyl)thiourea
30 MS-0062 2-Ethyl-2-{[(2-ﬂuorobenzyl)oxy]methyl}-5,5-dimethyltetrahydrofuran
31 MS-3556 2-(3-Isopropoxyphenyl)-1-ethanamine
32 3F-004 2-Morpholino-2-oxoacetohydrazide
33 1M-918 1-[(3-Methoxypropyl)amino]-3-[(2-methyl-1H-indol-4-yl)oxy]-2-propanol
34 6W-0328 Ethyl 4-chloro-1-(4-chlorophenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
35 10N-835 7-Chloro-N-(3-methoxybenzyl)-4-quinazolinamine
36 12N-055 6,7-Dimethoxy-N-(2-thienylmethyl)-4-quinazolinamine
37 4X-0854 2-{[4-(2-Chloroacetyl)-1H-pyrrol-2-yl]methylene}malononitrile
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The cross-reactivity predictions provided by CGBVS also offer
a promising approach for scaffold hopping in drug discovery.
For example, many small ligands for non-peptidergic GPCRs
were predicted to interact with peptidergic GPCRs as well,
indicating that CGBVS has further potential in the discovery of
novel non-peptidergic compounds for peptidergic receptors by
using these small ligands as reference molecules.
GPCR ligand screening
Although preliminary results indicated that CGBVS was useful
for identifying polypharmacological relationships among
ligands for the GPCR family, all of the analyzed compounds
were known GPCR ligands and, therefore, represent a very
limited number of examples within the vastness of chemical
space. The true value of CGBVS in lead discovery must be
tested by assessing whether this method can identify scaffold-
hopping lead compounds from a set of compounds that is
structurally more diverse. To assess this ability, we analyzed
11500 compounds from the Bionet chemical library (Key
Organics Ltd, Cornwall, UK) to predict compounds likely to
bind to two GPCRs from different subfamilies, ADRB2 and
NPY1R (Supplementary Table S7).
The 30 highest-scoring compounds for ADRB2 were tested
in calcium mobilization assays, in which nine compounds (hit
rate¼30%) exhibited either half-maximal effective concentra-
tions (EC50) or half-maximal inhibitory concentrations (IC50)
between 0.7nM and 65mM. These results suggest that CGBVS
is highly capable of mining of general chemical libraries
(Figure 4A and B, Supplementary Figure S5A and B, and
Supplementary Table S8A). For NPY1R, the 20 highest-scoring
compounds were tested in cAMPassays. Of these compounds,
three (hit rate¼15%) exhibited agonist activity with EC50
values of 16, 16, and 63mM (Figure 4C, Supplementary Figure
S5C and D, and Supplementary Table S8B).
Despite the fact that these EC50 values were in the
micromolar range, CGBVS could prove highly useful for lead
screening in drug development, as the lead-screening stage is
distinct from the optimization stage. For lead screening, it is
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left and the lower-right diagonal halves, respectively. Each value indicates the number of common ligands for each GPCR subfamily. For example, 1081 compounds
were reported to be ligands for amine receptors that cross-reacted with other amine receptors, and 14 amine receptor ligands were reported to cross-react with peptide
receptors.
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structures, rather than compounds with extremely high
activities in the nanomolar range, because lead candidates
are subsequently structurally optimized to generate higher
activity in the lead-optimization process.
Evaluation of ligand scaffold hopping
We next wanted to evaluate the extent of scaffold hopping
achieved in the identiﬁcation of these novel ligands. However,
so far no explicit deﬁnition of scaffold hopping exists.
Therefore, we began by establishing deﬁnitive criteria for
scaffold hopping through analysis of the structural relation-
ships between pairs of newly identiﬁed active compounds and
known ligands in the training data set by calculating their
maximum common substructures (MCSs). The number
of constituent atoms and bonds in the MCS is typically used
as a measure of structural similarity between two molecules.
We ﬁrst calculated MCSs for each Bionet active compound
against alloftheGPCRligandsinthetrainingdataset.Because
known GPCR ligands have diverse molecular scaffolds, we
selected a single ligand with the largest MCS value (max-MCS)
among all the calculated MCSs as the most relevant structure
for each active compound (shown in the middle column of
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Figure 4 Experimental conﬁrmation of in vitro GPCR activity of compounds and their scaffolds screened from a chemical library. Dose–response curves of the
top-ranked compounds from the Bionet chemical library for (A) ADRB2 agonists, (B) ADRB2 antagonists, and (C) NPY1R agonists. Inactive compounds (cutoff of
100mMi nE C 50/IC50 value) are not shown. Red lines indicate results for compounds exhibiting scaffold hopping based on the criteria explained in the Results section.
Blue lines indicate results from compounds with almost completely overlapping structures. Compounds 29 (N-(tert-butyl)-N0-(4-methoxybenzyl)thiourea), 30
(2-ethyl-2-{[(2-ﬂuorobenzyl)oxy]methyl}-5,5-dimethyltetrahydrofuran), and 5 are corresponding to the curves in A from left to right. Compounds 8, 33, 30, 28
(2-[2,5-dimethyl-4-(morpholinomethyl)phenoxy]acetamide), 31 (2-(3-isopropoxyphenyl)-1-ethanamine), 9 ((2-aminophenyl)(4-methylphenyl)amine), and 32
(2-morpholino-2-oxoacetohydrazide) are corresponding to the curves in B from left to right. Compounds 12, 34, and 15 (diethyl 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-
hydroxy-3,5-pyridinedicarboxylate) are corresponding to the curves in C from left to right. (D) Max-MCSs between identiﬁed active compounds (left) and the most
relevant compounds found within the entire training compound data set (center) or within the ligand set of each target protein (right) that exhibited scaffold hopping. The
max-MCSs between compounds are indicated in red. The columns ‘bioactivity’ and ‘ligand’ indicate the existence of publications regarding the active compound:
‘bioactivity’ indicates whether a publication has already described that the compound is bioactive; ‘ligand’ indicates whether a publication has uncovered the ADBR2/
NPY1R ligand activity, having known the compound is bioactive. All identiﬁed active compounds are shown in Supplementary Figure S9. See Table I for compound
names of the numbered compounds.
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ligand exhibiting the max-MCS from the subset of the training
data speciﬁc for ADRB2 and NPY1R (shown in the right
column of Figure 4D). When the two max-MCSs (shown as the
red colored substructures of Figure 4D) contained in these two
selected ligands did not overlap, the newly identiﬁed active
compound in the pair was deemed to have undergone scaffold
hopping. This can be a useful criterion for screening lead
compounds.
We performed scaffold-hopping analysis after having deﬁ-
ned the criterion. For example, compound 5 (2,5-dimethyl-1-
(2,2,4-trimethyl-2,3-dihydro-1-benzofuran-7-yl)-1H-pyrrole),
which showed weak ADRB2 agonist activity (Figure 4A), did
not exhibit overlapping substructure between the max-MCSs
of codeine (6) or iodocyanopindolol (7; Figure 4D), which
were selected from all the GPCRs and ADRB2 ligand sets,
respectively. Therefore, compound 5 was categorized as
representative of scaffold hopping. Indeed, the seven active
compounds (5, 9, 28–32), including scaffold-hopped com-
pound 5, identiﬁed as ADRB2 ligands did not contain an
oxypropanolamine moiety, an established constituent of
b-adrenergic blockers (Supplementary Tables S9 and S10A).
No biological activities have been reported for four (5, 28, 29,
and 30) of these compounds, whereas ADRB2 activities of
the rest compounds (9, 31, and 32) have not been reported
previously (see Supplementary information for details). In
contrast, compounds 8 (Sandoz-21-009) and 33 (1-[(3-methoxy-
propyl)amino]-3-[(2-methyl-1H-indol-4-yl)oxy]-2-propanol)
both showed strong ADRB2 antagonist activity and had max-
MCSs that overlapped with that of iodocyanopindolol (7),
a known ADRB2 ligand (Figure 4D and Supplementary Figure
S9A). These compounds were, therefore, categorized as non-
hopping, although these were originally reported as serotonin
receptor ligands and were thus not included in the training
data set for ADRB2. Indeed, this max-MCS contained a
representative moiety of b-adrenergic blockers (Supplemen-
tary Table S9). Compounds, such as this example with heavily
overlapping MCSs, could likely be identiﬁed using LBVS.
Nevertheless, max-MCS proﬁling analysis conﬁrmed the relia-
bility of our criteria for scaffold hopping, the accuracy
of predictions, and the reliability of the in vitro assays.
Furthermore, we identiﬁed the three novel active compounds
for NPY1R that have not previously been known to exhibit
biological activity. Of these compounds, compounds 12 (ethyl
1-(4-chlorophenyl)-4-[(4-methoxybenzyl)amino]-3-methyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxylate) and 34 (ethyl 4-chloro-1-
(4-chlorophenyl)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxy-
late) included examples of scaffold hopping (Figure 4D and
Supplementary Figure S9B).
Overall, CGBVS identiﬁed compounds for both GPCRs
analyzed that exhibited scaffold hopping, indicating that
CGBVS can use this characteristic to rationally predict novel
lead compounds, a crucial and very difﬁcult step in drug
discovery. This feature of CGBVS is critically different from
existing predictive methods, such as LBVS, which depend on
similarities between test and reference ligands, and focus on a
single protein or highly homologous proteins. In particular,
CGBVS is useful for targets with undeﬁned ligands, because
this method can use CPIs with target proteins that exhibit
lower levels of homology.
Application of CGBVS to kinase inhibitor
screening
Having demonstrated that CGBVS is a valuable strategy for
predicting CPIs for GPCRs,wealsowantedto showthe general
utility of this method for other target proteins. Therefore, we
selectedtheproteinkinasefamily,anotherpopularchemother-
apeutic target (Manning et al, 2002), for the application of
CGBVS. ACGBVS model for the kinase family was constructed
using a training data set of 15616 CPI samples (including 143
kinases and their 8830 inhibitors) from the GVK Biosciences
Pvt Ltd., (Hyderabad, India) kinase inhibitor database
(Supplementary Table S11). Similar to the GPCR results,
polypharmacological predictions for the kinases indicated
manypossible multiple interactions betweenkinases and their
ligands (Supplementary Figure S6). The analysis of ligand
promiscuity has shown that iodophenyl and polycyclic
aromatic groups (containing ﬁve-membered heterocycles)
are characteristic of the putatively promiscuous ligands
(Supplementary Figure S7 and Supplementary Table S12).
In particular, polycyclic aromatic compounds are likely to
interact across kinase subfamilies in a manner reminiscent of
staurosporine, a well-known promiscuous inhibitor (Karaman
et al, 2008).
We focused on two protein kinases, the epidermal growth
factor receptor (EGFR) tyrosine kinase and the cyclin-
dependent kinase 2 (CDK2) serine/threonine kinase. We ﬁrst
compared CGBVS with LBVS and SBVS by making predictions
using a validation data set that was designed for evaluation of
docking programs (Huang et al, 2006). For both kinases,
CGBVS was able to identify true inhibitors within the top-
ranked compounds more effectively than the LBVS and SBVS
methods (Supplementary Figure S8).
We then made prospective predictions for EGFR and CDK2
from the11500Bionetcompoundsandselected the20highest-
scoring compounds for experimental veriﬁcation (Supplemen-
tary Table S7). For EGFR, the off-chip mobility shift assay
revealed that 5 of the 20 compounds (hit rate¼25%) rankedby
CGBVS were inhibitors, with IC50 values between 0.014 and
13mM (Figure 5A, Supplementary Figure S5E and Supplemen-
tary Table S13A). However, MCS analysis suggested that these
compounds did not exhibit scaffold hopping (Figure 5C and
Supplementary Figure S9C). Indeed, the max-MCSs of four of
the active compounds (18, 21, 35, and 36) for EGFR were
quinazoline derivatives (Supplementary Tables S9 and S10B),
which are well-characterized EGFR inhibitors that include the
antitumor agent geﬁtinib. Compound 18 (6,7-dimethoxy-N-
phenyl-4-quinazolinamine) was shown to act as an EGFR
inhibitor. Although compounds 35 (7-chloro-N-(3-methoxy-
benzyl)-4-quinazolinamine) and 36 (6,7-dimethoxy-N-(2-thie-
nylmethyl)-4-quinazolinamine) were known to inhibit other
proteins such as NOD1 and STAT, their inhibitory activities
for EGFR have not been reported. No biological activities
have been reported for the remaining two compounds 21
(N-{2-[(4-chlorophenyl)sulfanyl]ethyl}-6,7-dimethoxy-4-qui-
nazolinamine) and 37 (2-{[4-(2-chloroacetyl)-1H-pyrrol-2-
yl]methylene}malononitrile).
For CDK2, 2 of the 20 compounds (hit rate¼10%) identi-
ﬁed had IC50 values of 4.9 and 19mM in the off-chip mobility
shift assay (Figure 5B, Supplementary Figure S5F and
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compounds also has not been reported previously. One active
compound, 23 ([2-(4-ﬂuorophenyl)-5,6,7,8-tetrahydroimida-
zo[2,1-b][1,3]benzothiazol-3-yl]methanol), was an example
of scaffold hopping (Figure 5C). This structure shared the
max-MCS of the imidazothiazole moiety with compound 24
(2-methyl-6-[6-(6-methyl-pyridin-2-yl)-imidazo[2,1-b]thiazol-
5-yl]-3a,7a-dihydro-benzooxazole), a known inhibitor of
transforming growth factor-b receptor type 1 tyrosine kinase,
unlike CDK2 serine/threonine kinase (Supplementary Table
S10B).
To assess prospective prediction performance of CGBVS
versus LBVS and SBVS, we have performed additional
experimental validation of the prediction results from LBVS
and SBVS for both EGFR and CDK2. Along with the validation
protocol for CGBVS, the off-chip mobility shift assays
conﬁrmed the bioactivities of the 20 highest-scoring Bionet
compounds that were selected by LBVS and SBVS. Conse-
quently, inhibitors were identiﬁed by LBVS for neither EGFR
nor CDK2 (Supplementary Figure S10A and B, and Supple-
mentary Table S14). SBVS identiﬁed one EGFR inhibitor
(IC50¼0.73mM) and one CDK2 inhibitor (IC50¼26mM), but
neither exhibited scaffold hopping (Supplementary Figure
S10C–G and Supplementary Table S15). The hit rate of
SBVS was 5% (1 hit out of 20 at 10mM), consistent with the
hit rate of SBVS previously reported (Shoichet, 2004). As
CGBVS exhibited 25 and 10% hit rates for EGFR and CDK2,
respectively, the prediction performance of CGBVS was
superior to those of existing methods (LBVS and SBVS) for
the kinase family as well. These results indicate that CGBVS
not only achieves higher hit rates but also predicts ligands
with scaffolds different from known ligands in the case of
protein kinases, suggesting that CGBVS is applicable to the
identiﬁcation of novel bioactive compounds for multiple
protein families.
Discussion
Whereas a critical ﬁrst step in drug development is the
identiﬁcation of compounds with novel scaffolds, the next
crucial step is assessment of selectivity. Information regarding
the novelty and selectivity of lead candidates obtained by
virtual screening can accelerate the subsequent lead-optimiza-
tion stage of drug development. A paradigmatic advantage of
CGBVS is the incorporation of multiple CPIs, numerically
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chemical structures and protein sequence data. In contrast,
LBVS uses only chemical descriptors in the feature vector.
This difference appears to provide CGBVS with a relatively
high ability to predict ligand binding to multiple proteins
(a measure of selectivity), while allowing scaffold hopping
through the use of CPIs. In fact, we observed a concomitant
loss of predictive performance when the number of elements
for protein vectors was reduced (Supplementary Figure S11).
The difference in the selectivity predictions of CGBVS and
LBVS can be explained by the absence of vector descriptors for
proteins in LBVS and the related lack of CPI data reﬂecting
ligand recognition. Machine learning with protein data sets
also enabled CGBVS to identify compounds that exhibited
scaffold hopping because CPIs could be subdivided into
chemical substructures and amino acid interactions, on which
SBVS relies. In CGBVS, CPIs were described as amino acid
versus chemical structure-derived feature vectors. CGBVS
predictions are based on extraction of conserved patterns
from subdivided interaction vectors involving both proteins
and their corresponding ligands. Our successful identiﬁcation
of novel, scaffold-hopping ligands indicates that these
conserved patterns included as yet undetermined signatures
in the multiple CPIs captured.
Recently, computational approaches conceptually similar to
our CGBVS approach have been proposed (Faulon et al, 2008;
Jacob and Vert, 2008; Wassermann et al, 2009). However,
these studies were limited in scope by the fact that they
focused on computational validation through retrospective
prediction andlackedexperimentalveriﬁcationoftheconcept.
Therefore, the practical utility and general applicability of
these methods, speciﬁcally aimed at novel lead identiﬁcation,
are questionable.
Ourpresentstudyhasdemonstratedthatchemicalgenomics
data are of immense practical use for lead discovery.
Importantly, in further comparative analyses of the virtual
screening of 11500 Bionet compounds, the novel compounds
that we identiﬁed using CGBVS were not in the high-scoring
range using LBVS or SBVS (Supplementary Figure S12).
Combining CGBVS with conventional methods, such as SBVS
and LBVS, can signiﬁcantly enhance the power of in silico
strategies.
In the present form, as a learning machine, we used a SVM,
which models the two class patterns of interacting pairs and
non-interacting pairs by using proteins and their ligands.
Therefore, the quality of these two types of training data has
much effect on the prediction performance. In this study, we
used manually curated protein–ligand interaction data sets
from the GLIDA and GVK Biosciences databases. However,
even curateddata setsarelikelytocontain somefactual errors,
which tend to reduce the effectiveness of machine-learning
methods. Therefore, improvement in the quality and quantity
of the training data resource could enhance the prediction
accuracy. A frequent hurdle to overcome when using CPI data
is the acquisition of reliable data representing non-interacting
pairs of ligands and their targets. Our strategy was to generate
the same quantity of negative data from unknown interactions
as that available for known interactions. The potential
drawback is the possible introduction of a small number of
false-negativeexamplesinwhichtheliganddoesinfactbindto
the target. The publication of experimentally conﬁrmed non-
interactions would beneﬁt the CGBVS strategy greatly.
Moreover, it is not easy to comprehensively retrieve enough
reliable activity information (that is, IC50,E C 50, Ki value, etc.)
about ligands because our available CPI databases consist of
heterogeneous experimental results from many researchers
who screened different compound sets for their targets of
interest using their original bioassay systems. If we could
obtain sufﬁcient and non-biased quantitative afﬁnity data and
generate a regressor model such as support vector regression,
the prediction performance might be further improved.
Although the traditional drug design process focused on
designing a single ligand speciﬁcally for a single receptor
molecule, our results suggest that a systems biology-based
‘integrationist mindset’ (Peterson, 2008) is more appropriate
for understanding and computing complex systems in some or
all of their entirety. Although the integrationist view is a
relatively recent approach that drug discovery research has
not embraced completely, the view is beginning to receive
attentionforsuchresearch.Recently,drugsthattargetmultiple
proteins have been attracting interest for the development of
novel effective therapeutics (Roth et al, 2004a; Fliri et al, 2005;
Morphy and Rankovic, 2007; Apsel et al, 2008). As a predic-
tive model, CGBVS could provide an important step in the
discoveryofsuchmulti-targetdrugsbyidentifyingthegroupof
proteins targeted by a particular ligand, leading to innovation
in pharmaceutical researches.
Materials and methods
CPI data
Data for 5207 ligand–GPCR pairs (including 317 GPCRs and their 866
ligands) with known CPIs were collected from the GLIDA database
(Okuno et al, 2006), and 15616 inhibitor–kinase pairs (including 143
kinases and their 8830 inhibitors) were collected from the GVK
Biosciences kinase inhibitor database. The GLIDA database was
constructed from several reliable resources, including IUPHAR-RD
(Foord et al, 2005), PubMed (http://www.ncbi.nlm.nih.gov/pubmed/),
PubChem (Wang et al, 2009), DrugBank (Wishart et al, 2006), the
Ki Database (Roth et al, 2004b), and MDL ISIS/Base 2.5. Then, we
carefully checked each compound against the primary literature to
ensure that the chemical structure, target protein name, and binding
and activity information were correct. Although the number of GPCR
ligands was relatively small, the CPI pairs represent a credible data set
because only interactions with relatively high afﬁnities (Ki,E C 50, and
IC50o1mM) are deposited in the GLIDA database.
Chemical and protein descriptors
Chemical descriptors were calculated using the DRAGONX program
(version 1.2; Talete S.r.l., Milan, Italy). Protein descriptors were
calculated from the sequences alone. Speciﬁcally, dipeptide composi-
tion-based description (a mismatch-allowed spectrum kernel) was
used to represent GPCRs, providing 400 dimensions (Leslie et al,
2004). For kinases, we used descriptors consisting of 1497 features
provided by the PROFEAT Webserver (Li et al, 2006). Calculations of
these descriptors were applied to the kinase domain, not to full-length
sequences. Finally, these descriptor vectors were separately scaled to
the range  1t o1 .
SVM calculations
SVM calculations for CGBVS used a portion of the LIBSVM suite
of programs (http://www.csie.ntu.edu.tw/~cjlin/libsvm). The
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optimized using a grid search.
Retrospective virtual screening for ADRB2 by
CGBVS
A predictive model for ADRB2 was constructed using a 5207-CPI pair
data set, but excluding 40 ADRB2-related CPIs, leaving 5167 pairs.
Thenumberofpredictedcompoundswas866(includingthe40known
ligands). We then combined the chemical descriptors for these
compounds and the protein descriptors for ADRB2, and predicted
the probability of interactions. The ligand prediction was repeated 20
times withdifferent negative sample sets, and the prediction scorewas
set to the maximum probability.
Retrospective virtual screening for ADRB2 by
SBVS
We used the recently published crystal structure of ADRB2 (Cherezov
et al, 2007) as a starting model. The ADRB2 structure and the 866
known ligands were prepared for docking simulations using the
Protein Preparation Wizard and LigPrep script within Maestro
(Schro ¨dinger Inc,Portland, OR), respectively. This protein preparation
procedure involved optimizing contacts by changing hydroxyl group
orientations, ﬂipping Asn and Gln side chains, and selecting His
tautomeric states, followed by reﬁning energy constraints using the
OPLS-AA force ﬁeld. Glide (SP mode) (Friesner et al, 2004) was used
for grid generation and rigid receptor docking of the ligands. During
the simulations, ﬁve docking models for each ligand were predicted,
and the model with the minimum GlideScore was chosen as the ﬁnal
docking structure. SBVS was performed under two conditions:
(1) without constraints, and (2) with constrained hydrogen bonding
betweenthecompoundsandAsp113,aresiduepreviouslyshowntobe
crucial for ligand binding (Strader et al, 1987). The different screening
approaches were evaluated in terms of the hit rate and the EF
(Supplementary Table S3) using the following equations:
Hitrate ¼ 100 ðHitssampled=NsampledÞ;
whereNsampledrepresentsthetotalnumberofhigh-scoringcompounds
and Hitssampled represents the number of active compounds, and
EF ¼ð Hitssampled=NsampledÞ=ðHitstotal=NtotalÞ
whereNtotalrepresentsthetotalnumberofcompoundsinthecomplete
database and Hitstotal represents the number of active compounds
therein. Thesevalueswere calculated based on the assumption that all
compounds reported to interact with ADRB2 were truly active
compounds and that those with unknown activity for the target were
inactive.
Retrospective virtual screening for kinases
EGFR and CDK2 were chosen for model validation. In total, 15616
kinase–inhibitor pairs were used to construct a CGBVS model. First,
validation data sets from the DUD website (http://dud.docking.org/)
were used (Huang et al, 2006). Compounds duplicated in the training
and test data sets were removed from the test data. For comparison,
binding free energy data, calculated by DOCK (Makino and Kuntz,
1997), was downloaded from the DUD site. Grid generation and rigid
receptor ligand docking was performed using another SBVS method,
GOLD (Jones et al, 1997). During simulations, three docking models
for each ligand were predicted, and the model with the minimum
ChemScore (or Astex Statistical Potential) was chosen as a ﬁnal
docking structure. Prospective predictions were generated for EGFR
and CDK2 using 11500 Bionet compounds (Key Organics Ltd), and the
20 highest-scoring compounds were selected for experimental
veriﬁcation (See Supplementary Table S7 for compound ID, names,
and scores, and Supplementary Data Set 1 for chemical structures of
the Bionet compounds).
Polypharmacological prediction and prospective
virtual screening by CGBVS
A prediction model for ADRB2 was constructed for CGBVS as
described for retrospective screening, with the exception that all
interaction data were included in the training data set. A prediction
model for NPY1R was constructed using the 5207 CPI samples and an
additional 3106 CPI samples of peptidergic GPCRs from the Integrity
database (Prous Science S.A., Tokyo, Japan). Similarly, a prediction
model for kinases was constructed using 15616 CPI samples from the
GVK Biosciences kinase inhibitor database. In each case, 11500
compounds from the Bionet compound set were screened by CGBVS.
MCS identiﬁcation for active compounds
MCSs for each active compound and every GPCR ligand (or kinase
inhibitor) in the training data set were calculated using the LibMCS
program in the JChem module (Csizmadia, 2000). A single known
ligand with the highest MCS value (max-MCS) was selected as the
mostrelevantstructureforeachactivecompound. Forcomparison,we
also selected a compound with the max-MCS compared with known
ligands of the test receptor from the training data. Scaffold hopping
was deﬁned as the absence of overlaps between these max-MCSs.
Experiments and the other calculations
A detailed description of the applied experimental and other
computational techniques is given in the Supplementary information.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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